Cremer A, Enssle JC, Pfaff S, Kouidri K, et al. Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML. Ann Hematol 2023;102:2903-2908.
PMID: 37552323